Myeloproliferative Neoplasms Highlights from ASCO & EHA 2023

Virtual webinar featuring presentations & discussions on selected abstracts

Chaired by Claire Harrison
Moderators: Deepti Radia, Haifa Kathrin Al-Ali

27 June, 12:30 EST / 17:30 BST / 18:30 CET

Apply for registration here

Agenda:

17:30 – 17:35
Welcome & Introductions – Claire Harrison

17:35 – 18:05
Session 1

• Efficacy and safety of Luspatercept for the treatment of Anemia in patients with Myelofibrosis: Results from the ACE-536-MF-001 study; EHA S167
  Francesco Passamonti
   
• Selective JAK2/IRAK1/ACVR1 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation in Myelofibrosis: Final analysis of the Phase II Hovon-134 trial; EHA S249
  Ruben Van Dijck 

• Spleen volume reduction predicts survival in Myelofibrosis patients on Pacritinib but not best available therapy: Persist-2 landmark overall survival analysis. EHA P20010
  Jan Bewersdorf

Panel discussion   

18:05-18:40
Session 2 

• ASCO Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034. ASCO 7063
  Srinivas Tantravh

• Phase 1/2 study of the activin receptor-like kinase 2 (alk2) inhibitor Zilurgisertib (incb000928, limber-104) as monotherapy or with Ruxolitinib in patients with Anemia due to myelofibrosis. EHA -P1022
  Prithviraj Bose  

• An open-label, global, Phase (ph) 1b/2 study adding Navtemadlin (NVTM) to Ruxolitinib (RUX) in patients (pts) with primary or secondary Myelofibrosis (MF) who have a suboptimal response to RUX. EHA S210
  John Mascarenhas

• BMS-986158, a potent bet inhibitor, as monotherapy and in combination with Ruxolitinib or Fedratinib in intermediate- or high-risk Myelofibrosis (MF): results from a Phase 1/2 study. EHA S213
  Haifa Kathrin Al-Ali

Panel discussion 

18:40-19:15
Session 3

• MYLOX-1: A Phase II study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral LOXL2 inhibitor GB2064 (with focus on bone marrow collagen) in patients with Myelofibrosis. EHA P2014
  Clair Harrison  

• A pilot study of the Anti-slamF7 monoclonal antibody, Elotuzumab, in patients with Myelofibrosis. EHAP1025
  Prithviraj Bose
   
• Preliminary data from the Phase 1/2 study of TP3654, an investigational selective PIM1 Kinase inhibitor, showed Cytokine reduction and clinical responses in relapsed/refractory Myelofibrosis. EHA P1031
  Firas El Chaer
   
• L-895, a first-in-class, covalent Bruton Tyrosine Kinase inhibitor (BTKI) for the treatment of Myelofibrosis (MF) patients (PTS) with severe Thrombocytopenia (PLATELETS (PLTS) <50 K/UL). EHA P1038
  Michael Loschi

Panel discussion 

19:15-19:50
Session 4

• Pelabresib (CPI-0610) monotherapy in patients with high-risk essential Thrombocythemia refractory or intolerant to Hydroxyurea: preliminary results from manifest study. S168
  Francesco Passamonti

• Update on Avapritinib
  Deepti Radia

• JAK2-CHIP is associated with similar risk of cardiovascular disease as JAK2-MPNs. EHA P1029
  Jeremy Grevet

• Rusfertide (PTG-300) improves Polycythemia Vera (PV) related symptoms in PV patients. EHA P1016
  Andrew Kuykendall 

Panel discussion 

19:50-19:55
Conclusions and close of meeting

Please note that registration is open to healthcare professionals only and registration is subject to approval.
Your application will be reviewed and confirmed by email.

The Post-ASCO & EHA 2023 MPNs Highlights webinar has been supported by:

Silver Supporters